Ali Health, a shareholder of Chinese Health, plans to reduce its shareholding by no more than 12 million shares; shareholders of Aoride, Qiongcun Kunsun, plan to reduce their shares by a total of no more than 3%; the controlling shareholder and actual controller of Chuangshi Technology received a notice from the procuratorial agency; Jinlong Machinery & Electronic stated that it reported a related embezzlement case and received a notice of case filing; Ningbo Techmation stated that the Italian EEI company does not directly produce or develop fusion reactor devices; Tasly Pharmaceutical Group has suspended the clinical trial of Anmei monoclonal antibody.